ClinicalTrials.gg
Not yet recruitingNCT07305311Updated Dec 26, 2025

Characterising the Network-Specific Effects of Piriform Cortex Stimulation Via SEEG

An interventional study of SEEG recordings and SPES in Refractory Epilepsy and Neuromodulation, sponsored by Xuanwu Hospital, Beijing. Not yet recruiting at 1 site in China. Open to participants aged 14 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-26.

Sponsored by Xuanwu Hospital, Beijing · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
14 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing — 11 open to participants now, 12 under way, none of them phase 3. Drug Resistant Epilepsy · Xuanwu Hospital, Beijing.

Planned enrollment
7th of 12
10 · median 13
Started
2025
with 1 other
No phase
10 of 15
7 open now
Primary completion
2027-01
later than 7 of 11 live
Registered
14th of 15
by date

Among the 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2025, is one of 10 with no phase, reaches primary completion later than 7 of the 11 other live ones, and was the 14th registered.

Drug Resistant Epilepsy

258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.

Browse Drug Resistant Epilepsy studies →

Open to participants now

11 of the 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.

This study: 14 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Drug Resistant Epilepsy by Xuanwu Hospital, Beijing, or all of them as a file.
02

Study summary

The prospective study aims to characterize the network-specific modulatory effects of piriform cortex stimulation in patients undergoing stereotactic EEG for drug-resistant epilepsy. Using multimodal data, it seeks to link stimulation-evoked electrophysiological responses across brain networks with clinical outcomes, to inform targeted neuromodulation therapies.

Read the detailed description

This study employs stereotactic electroencephalography (SEEG) to investigate the network-specific mechanisms of brain modulation induced by electrical stimulation of the piriform cortex. By analyzing high-density intracranial recordings, combined with structural and functional neuroimaging, the research systematically characterizes how focal stimulation differentially engages and reorganizes activity across large-scale neural circuits. The primary focus is to decode the electrophysiological signatures of network engagement-including changes in spectral power, phase synchronization, and information flow-to reveal fundamental principles of targeted neuromodulation in the human brain.

03

Conditions studied

  • Refractory Epilepsy
  • Neuromodulation

Keywords

  • SEEG
  • Piriform cortex
  • Electrical stimulation
  • Electrophysiology
04

Who can participate

Ages eligible
14 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patients were diagnosed with drug-resistant epilepsy.
  • The patients underwent stereoelectroencephalography (SEEG) implantation for pre-surgical evaluation of epilepsy, with at least one electrode target reaching the piriform cortex
  • Participants/parents/legal guardian provide for inclusion

Exclusion criteria

Exclusion Criteria:

  • Subjects that experience surgical complications during the implant procedure will be excluded from the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    SEEG recordings and SPES effects

    This arm encompasses patients with drug-resistant focal epilepsy who underwent intracranial monitoring via stereotactically implanted depth electrodes (SEEG) as part of their standard presurgical evaluation. During the monitoring period, these patients additionally underwent systematic Single-Pulse Electrical Stimulation (SPES) mapping. SPES was administered according to a standardized clinical protocol, involving the delivery of single, low-intensity electrical pulses to selected electrode contacts-including those located within or adjacent to the piriform cortex-while recording the evoked electrophysiological responses across the implanted SEEG network. The data collected in this arm include continuous intracranial EEG recordings, precise stimulation parameters (location, intensity), and the corresponding electrophysiological responses used to characterize cortico-cortical evoked potentials and network connectivity.

    Device: SEEG recordings and SPES

Interventions

  • DeviceSEEG recordings and SPES

    The intervention involves single-pulse electrical stimulation (SPES) applied during stereotactic electroencephalography (SEEG) monitoring. Low-intensity, standardized electrical pulses are delivered to targeted contacts within or near the piriform cortex via implanted depth electrodes, while simultaneous full-bandwidth SEEG recordings capture network-wide electrophysiological responses, allowing characterization of stimulation-evoked brain network activation and modulation patterns.

06

What researchers measure

Primary outcomes

  1. Seizure Discharge Suppression Rate

    Quantified as the percentage reduction in the frequency of spikes and interictal epileptiform discharges (IEDs) during active stimulation compared to the baseline period.

    Time frame: 72 hours

Secondary outcomes

  1. Single-Pulse Stimulation Amplitude:

    The minimum current intensity (mA) required to elicit a reproducible response.

    Time frame: 72 hours

  2. N1 Component Amplitude and Latency:

    Amplitude (μV) and latency (ms) of the primary cortical evoked response (N1 wave).

    Time frame: 72 hours

  3. Spatial Distribution of Activation

    The extent of cortical activation, assessed by the number of electrode contacts showing significant evoked responses.

    Time frame: 72 hours

  4. Effective Connectivity Change:

    Alterations in effective connectivity strength (e.g., measured by Granger causality within a 500 ms time window).

    Time frame: 72 hours

  5. Phase-Amplitude Coupling Index

    Changes in coupling between the phase of low-frequency oscillations and the amplitude of the gamma band (30-80 Hz).

    Time frame: 72 hours

  6. Functional Network Reconfiguration

    Changes in node centrality metrics (e.g., betweenness centrality, degree centrality) based on graph-theoretical analysis of functional networks.

    Time frame: 72 hours

  7. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Adverse Events: Incidence and severity of adverse events specifically associated with piriform cortex stimulation.

    Time frame: 72 hours

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Jan 2027, 13 months later.

Of 90 non-industry interventional studies with no phase under Drug Resistant Epilepsy, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21. This study's planned 13 months is below that.

Counting every sponsor, half of 102 studies reached it within 34 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Dec 26, 2025
StartEst.
Dec 8, 2025
Primary completionEst.
Jan 8, 2027
CompletionEst.
Nov 8, 2027
Last update
Dec 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07305311
Responsible party
Liankun_Ren (professor, Xuanwu Hospital, Beijing) — Principal investigator
First posted
Dec 26, 2025
Start date
Dec 8, 2025 (estimated)
Primary completion
Jan 8, 2027 (estimated)
Completion
Nov 8, 2027 (estimated)
Last update
Dec 26, 2025

Study contacts

Liankun Ren, MD
Contact
renlk2022@outlook.com
13681576621
Liankun Ren
principal investigator · Xuanwu Hospital, Beijing

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion